Evidence map›Paper›PMID 35423091›Full record

ArticleRSC advances2021

Electrospun collagen core/poly-l-lactic acid shell nanofibers for prolonged release of hydrophilic drug.

Wan-Ying Huang, Toshiya Hibino, Shin-Ichiro Suye, Satoshi Fujita

Abstract read
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wan-Ying HuangDepartment of Frontier Fiber Technology and Science, Graduate School of Engineering, University of Fukui 3-9-1 Bunkyo Fukui 910-8507 Japan fujitas@u-fukui.ac.jp.
Toshiya HibinoDepartment of Frontier Fiber Technology and Science, Graduate School of Engineering, University of Fukui 3-9-1 Bunkyo Fukui 910-8507 Japan fujitas@u-fukui.ac.jp.
Shin-Ichiro SuyeDepartment of Frontier Fiber Technology and Science, Graduate School of Engineering, University of Fukui 3-9-1 Bunkyo Fukui 910-8507 Japan fujitas@u-fukui.ac.jp.
Satoshi FujitaDepartment of Frontier Fiber Technology and Science, Graduate School of Engineering, University of Fukui 3-9-1 Bunkyo Fukui 910-8507 Japan fujitas@u-fukui.ac.jp.ORCID https://orcid.org/0000-0003-1438-6402

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of sustained control drug release for delivering hydrophilic drugs has been challenging due to a burst release. Nanofibers are used as materials that enable efficient drug delivery systems. In this study, we designed drug-encapsulated core-shell nanofibers comprising a hydrophilic core of collagen (Col) incorporated with berberine chloride (BC), an anti-inflammatory and anti-cancer agent used as a model drug, and a hydrophobic shell of poly-l-lactic acid (PLLA). Long-term drug release profiles under both the physiological and hydrolysis-accelerated conditions were measured and analyzed using a Korsmeyer-Peppas kinetics model. We found that the Col/PLLA core-shell fiber achieved a controllable long-term release of the hydrophilic drug incorporated inside the core by the slow degradation of the PLLA shell to prevent the burst release while PLLA monolithic fibers showed early release due to the dissolution of drug and the following rapid hydrolysis of fibers. As shown by the results of Col/PLLA core-shell fiber under a hydrolysis-accelerated condition to promote the release of drugs test, it would provide sustained release over 16 days under physiological conditions. Here, the development of the nanomaterial for the long-term drug release of hydrophilic drugs was achieved, leading to its potential medical application including cancer treatment.

Identifiers

PMID35423091
PMCPMC8694765

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.